Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice

Autor: Tanaka, Toshihiro, Ueno, Miho, Nakashima, Yuta, Chinen, Shotaro, Sato, Eiichi, Masaki, Michio, Mogi, Ai, Sasaki, Hidenori, Tamura, Kazuo, Takamatsu, Yasushi

Publikováno v: Thoracic Cancer

Background Evidence of eribulin therapy for metastatic breast cancer (MBC) in clinical practice is not well documented. Methods We retrospectively analyzed the safety and efficacy of eribulin in 29 MBC patients from 2011 to 2016 at Fukuoka University

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b452af47583ac0b8f54898c2480fd146
http://europepmc.org/articles/PMC5588851

Acute megakaryoblastic leukaemia with t(1;22)(p13·3;q13·1)/RBM15‐MKL1 in an adult patient following a non‐mediastinal germ cell tumour.

Autor: Saito, Yo, Makita, Shinichi, Chinen, Shotaro, Kito, Momoko, Fujino, Takahiro, Ida, Hanae, Hosoba, Rika, Tanaka, Takashi, Fukuhara, Suguru, Munakata, Wataru, Suzuki, Tatsuya, Maruyama, Dai, Miyagi‐Maeshima, Akiko, Matsushita, Hiromichi, Izutsu, Koji

Publikováno v: British Journal of Haematology; Sep2020, Vol. 190 Issue 6, pe329-e332, 4p

Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.

Autor: Inoue Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Okamoto H; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Miyashita A; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Kawaji-Kanayama Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Chinen S; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Fujino T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Tsukamoto T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Shimura Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Mizutani S; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Kaneko H; Department of Hematology, Aiseikai Yamashina Hospital, Kyoto 607-8086, Japan., Kuwahara-Ota S; Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto 603-8151, Japan., Fuchida SI; Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto 603-8151, Japan., Nishiyama D; Department of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Kyoto 620-0056, Japan., Hirakawa K; Department of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Kyoto 620-0056, Japan., Uchiyama H; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan., Uoshima N; Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, Japan., Kawata E; Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Osaka 570-8540, Japan., Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

Publikováno v: Oncology letters [Oncol Lett] 2023 Dec 18; Vol. 27 (2), pp. 62. Date of Electronic Publication: 2023 Dec 18 (Print Publication: 2024).

Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen.

Autor: Mogi A; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan., Sasaki H; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan., Nakashima Y; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan., Chinen S; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan., Ishizu M; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan., Tanaka T; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan., Takata T; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan., Takamatsu Y; Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan.

Publikováno v: Journal of clinical and experimental hematopathology : JCEH [J Clin Exp Hematop] 2020 Sep 25; Vol. 60 (3), pp. 73-77. Date of Electronic Publication: 2020 Aug 08.